德斯控股2022中期报告

CHARACTERISTICSOFGEMOFTHESTOCKEXCHANGEOFHONGKONGLIMITED(THE“STOCKEXCHANGE”) GEMhasbeenpositionedasamarketdesignedtoaccommodatesmallandmid-sizedcompaniestowhichahigherinvestmentriskmaybeattachedthanothercompanieslistedontheStockExchange.Prospectiveinvestorsshouldbeawareofthepotentialrisksofinvestinginsuchcompaniesandshouldmakethedecisiontoinvestonlyafterdueandcarefulconsideration. GiventhatthecompanieslistedonGEMaregenerallysmallandmid-sizedcompanies,thereisariskthatsecuritiestradedonGEMmaybemoresusceptibletohighmarketvolatilitythansecuritiestradedontheMainBoardandnoassuranceisgiventhattherewillbealiquidmarketinthesecuritiestradedonGEM. HongKongExchangesandClearingLimitedandtheStockExchangetakenoresponsibilityforthecontentsofthisreport,makenorepresentationastoitsaccuracyorcompletenessandexpresslydisclaimanyliabilitywhatsoeverforanylosshowsoeverarisingfromorinrelianceuponthewholeoranypartofthecontentsofthisreport. Thisreport,forwhichthedirectors(the“Directors”)ofRMHHoldingsLimited(the“Company”,togetherwithitssubsidiaries,the“Group”)collectivelyandindividuallyacceptfullresponsibility,includesparticularsgivenincompliancewiththeRulesGoverningtheListingofSecuritiesonGEMoftheStockExchange(the“GEMListingRules”)forthepurposeofgivinginformationwithregardtotheCompany.TheDirectors,havingmadeallreasonableenquiries,confirmthattothebestoftheirknowledgeandbelief,theinformationcontainedinthisreportisaccurateandcompleteinallmaterialrespectsandnotmisleadingordeceptive,andtherearenoothermatterstheomissionofwhichwouldmakeanystatementhereinorthisreportmisleading. 香交所港”联）G合E交M易的所特有色限公司（“联 G个E上M市的的定市位场，乃，此为等中公小司型相公比司起提其供一他在险。联有交意所投上资市的的人公士司应带了有解较投高资投于资风该等详的公考司虑的后潜方在作风出险投，资并决应定经。过审慎周 由于司，在GEM上市公司普遍为中小型公 板买卖G的E证M买券卖承的受证较券大可的能市会场较波于动风主险会，有同高时流无通法量保的证市在场。GEM买卖的证券 本报告乃遵照联交所则（“GEM证券上市规 香所港对交本易报及告结的算内所容有概限不公负司责以，对及其联交准确明确性表或示完概整不性就亦因不本发报表告任全何部声或明任，何并部引致分的内任容何而损产失生承或担因任倚何赖责该任等。内容而 关德斯GE控M股上有市限规公则司”（）“的本规公定司而”提，连供有同其公附司属各公董司事（统“称董“事本”）集愿团就”）本的报资告料共。同本及合个理别查承询担后，全确部认责就任彼，并等于所作深出知一及切深信属：准本确报及完告整所，载且资无料误在导各或重欺大诈方成面份均；及所载并任无何遗声漏明任或何本其报他告事产项生致误使导本。报告 摘要 Highlights •TheunauditedrevenueoftheGroupamountedtoapproximatelyS$7,713,000forthesixmonthsended30June2022,representinganincreaseofapproximatelyS$3,090,000or66.8%ascomparedwiththerevenueofapproximatelyS$4,623,000forthesixmonthsended30June2021. •TheunauditedlossoftheGroupwasapproximatelyS$4,948,000forthesixmonthsended30June2022,representinganincreaseofapproximatelyS$2,119,000or74.9%ascomparedwiththelossesofapproximatelyS$2,829,000forthesixmonthsended30June2021.Thelossesmainlyattributableto(i)employeebenefitsexpenseamountingtoapproximatelyS$4,274,000,representinganincreaseofapproximatelyS$1,585,000or58.9%,ascomparedwithsixmonthsended30June2022additionalheadcountsoftheGroup;(ii)theincreaseofoperationalcosts;and(iii)unrealisedlossoffairvaluethroughprofitorlossinstruments.Besides,wetrendfordoctorstobesalarymodelaspartofafoundationandretentionpurpose.Wehave1newdermatologistundersalarymodeljoinedusduringfirstquarterofyear2022.Wehavetotal9dermatologistswithcompositionofsalarymodelandcommissionmodel.Ontheotherhand,othermiscellaneousexpensesleadtheincreaseofotheroperatingexpenses. •Losspersharewas0.44Singaporecentsforthesixmonthsended30June2022whilethelosspersharewas0.40Singaporecentsforthesixmonthsended30June2021. •TheBoarddidnotrecommendthepaymentofaninterimdividendforthesixmonthsended30June2022. • 至2021年6月30日止六个月的收益约4,623,000新加坡元增加约3,090,000新加坡元或 本集团截至2022年6月30日止六个月的未经审核收益约为7,713,000新加坡元，较截 66.8%。 • 至2021年6月30日止六个月的亏损约2,829,000新加坡元增加约2,119,000新加坡元或 本集团截至2022年6月30日止六个月的未经审核亏损约为4,948,000新加坡元，较截 74.9%。该亏损主要归因于(i)雇员福利开支约4,274,000新加坡元，较本集团截至2022年6 月30 及(iii)按公平值计入损益具的未变现亏损。此外，我们倾向于为医生设为薪金模式， 日止六个月的额外人数相比增加约 1,585,000 新加坡元或 58.9% ； (ii) 运营成本增加； 以作为基础及挽留目的的一部分。于2022 式加入我们。我们共有9名皮肤科医生按薪金模式及佣金模式组合受薪，另一方面，其他 年第一季度，我们有 1名皮肤科医生按薪金模 杂项开支导致其他经营开支增加。 •截至2022年6月30日止六个月的每股亏损为0.44新加坡仙，而截至2021年6月30日止六 • 个月的每股亏损则为0.40新加坡仙。 董事会不建议就截至2022年6月30日止六个月派付中期股息。 RMHHOLDINGSLIMITEDInterimReport20221 未经审核中期业绩 UnauditedInterimResults TheboardofDirectors(the“Board”)ispleasedtoannouncetheunauditedcondensedconsolidatedresultsoftheGroupforthesixmonthsended30June2022,togetherwiththecomparativefiguresforthecorrespondingperiodin2021,asfollows: 董至2事0会2（2“年董6月事3会0日”）止谨六此个公月布的本未集经团截审核比较简数明字综如合下业：绩，连同2021年同期的 简明综合损益及其他全面收益表 CondensedConsolidatedStatementofProfitorLossandOtherComprehensiveIncome 截至年月日止六个月 Forthesixmonthsended30June20222022630 截至月日止三个月截至月日止六个月 Threemonthsended30June Sixmonthsended30June 2德斯控股有限公司2022中期业绩报告 630630 年年年年 2022202120222021 2022202120222021 附注千新加坡元千新加坡元千新加坡元千新加坡元 NotesS$’000S$’000S$’000S$’000 （未经审核）（未经审核）（未经审核）（未经审核） (Unaudited)(Unaudited)(Unaudited)(Unaudited) Revenue收益5Otheroperatingincome其他经营收入6Consumablesandmedical已用消耗品及 suppliesused医疗用品 Otherdirectcosts其他直接成本Employeebenefitsexpense雇员福利开支Amortisationofintangibleassets无形资产摊销Depreciationofplantand厂房及设备折旧 equipment Depreciationofright-of-use使用权资产折旧 assets Otheroperatingexpenses其他经营开支Reversalofimpairmentlosson拨回其他应收款项 otherreceivables的减值亏损 Financecost